amifostine anhydrous and Injuries, Radiation studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Research Excerpts

Excerpt	Relevance	Reference
" Professionals discussed a novel treatment (Irinotecan) for advanced colorectal cancers; a unique anticancer agent (Docetaxel) effective in hard-to-treat head and neck cancer; a highly active neoadjuvant chemotherapy regimen for operable breast cancer; and a cytoprotective agent (Amifostine) capable of protecting normal tissue from radiation and chemotherapeutic toxicity."	3.69	Highlights of the Eighth European Cancer Conference. ( Prescott, LM, 1995)
"Fifty-five patients with prostate cancer (T1-2 stage, Gleason score <7 and prostate specific antigen (PSA) <10 ng/ml) were treated with localized conformal 4-field radiotherapy to the prostate and seminal vesicles: 51 Gy were delivered (3."	2.76	Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. ( Giatromanolaki, A; Kalogeris, K; Koukourakis, MI; Kyrgias, G; Mavropoulou, S; Milioudis, N; Nassos, P; Panteliadou, M; Papadopoulou, A; Sivridis, E; Touloupidis, S, 2011)
"Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria."	2.75	Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. ( Bai, M; Batistatou, A; Briasoulis, E; Capizzello, A; Christodoulou, D; Karavasilis, V; Katsanos, KH; Panelos, I; Tolis, C; Tsekeris, P; Tsianos, EV, 2010)
"To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)."	2.74	A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. ( Hickey, G; Killion, L; Martin, C; Mauch, PM; Ng, AK; Rodrigues, NA; Silver, B; Stevenson, MA, 2009)
" There were no reports of Grade >/=3 amifostine-related adverse events."	2.73	Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. ( Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O, 2007)
"Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine."	2.72	Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. ( Aekmahachai, M; Chiewvit, S; Chitapanarux, I; Khorprasert, C; Kongthanarat, Y; Lorvidhaya, V; Panichevaluk, A; Phromratanapongse, P; Pusuwan, P; Ratchadara, S; Saengsuda, Y; Shotelersuk, K; Sirilipoche, S; Sukthomya, V; Suntornpong, N; Swangsilpa, T; Tesavibul, C; Veerasarn, V, 2006)
"The treatment of head and neck cancer continues to evolve."	2.71	Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. ( Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L, 2003)
" Four types of targeted adverse events were examined as to their occurrence and possible relationship with amifostine."	2.71	Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design. ( Chico, IM; Fullmer, K; Hirsch, RL; Samuels, MA, 2003)
"The degree of xerostomia has been reported to depend on the radiation dose and salivary gland volume irradiated."	2.71	Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. ( Chao, KS; Haughey, B; Thorstad, WL, 2003)
"The degree of xerostomia has been reported to depend on the radiation dose and volume of salivary gland irradiated."	2.71	Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. ( Chao, KS; Haughey, B; Thorstad, WL, 2004)
"In 16/39 patients (41%) amifostine was discontinued due to severe adverse effects, which led to discontinuation of the phase III study."	2.71	Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004)
" However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies."	2.71	Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. ( Axelrod, R; Byhardt, R; Komaki, R; Langer, C; Machtay, M; Movsas, B; Nicolaou, N; Sarna, L; Scott, C; Smith, C; Wasserman, T; Werner-Wasik, M, 2005)
"Acute esophagitis was scored weekly."	2.70	Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. ( Axelrod, RS; Chapman, AE; Curran, WJ; Deshields, M; Friedland, DP; Grubbs, S; Hauck, W; Rose, LJ; Werner-Wasik, M, 2002)
"Xerostomia was scored subjectively and by whole saliva measurements."	2.70	Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. ( Braaksma, M; Levendag, P, 2002)
"A phase II trial of SC amifostine in head and neck cancer was performed in a patient population (n = 54) similar to that studied in a phase III trial of intravenous amifostine to allow comparisons of outcomes."	2.70	Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. ( Anné, PR, 2002)
"Twenty-nine patients with localized prostate cancer were accrued."	2.70	Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. ( Ben-Josef, E; Biggar, S; Han, S; Kaplan, I; Kelly, L; Stamos, B; Tobi, M; Vargas, BJ, 2002)
" 5-FU chemotherapy was administered as 120-hours continuous infusion in the first and fifth radiation week via a central venous catheter in a daily dosage of 1,000 mg/m2."	2.69	Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. ( Dunst, J; Müller, AC; Pigorsch, S; Reese, T; Semlin, S, 2000)
"Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis."	2.69	Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Oster, W; Rudat, V; Russell, L; Sauer, R; Strnad, V; Wasserman, TH; Zhang, J, 2000)
"Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily x 5 schedule."	2.67	Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. ( Beitler, JJ; Bruckner, H; Goldberg, G; Haynes, H; Hochster, H; Holland, JF; Mandeli, J; Runowicz, C; Smith, H; Wadler, S, 1993)
"Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment, frequently resulting in acute skin and mucosal toxicities."	2.49	Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. ( Pace, MB; Radvansky, LJ; Siddiqui, A, 2013)
"radiotherapy plus amifostine for cancer treatment."	2.43	Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006)
"Radiation for head and neck cancers is often curative, but high doses are used."	2.43	How to reduce radiation-related toxicity in patients with cancer of the head and neck. ( Chambers, MS; Garden, AS; Lewin, JS, 2006)
"Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients."	2.43	Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. ( de Castro, G; Federico, MH, 2006)
"Most patients with locally advanced esophageal cancer die from their disease, despite complete surgical extirpation of tumor or institution of aggressive, multimodality treatment."	2.42	Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine? ( Jatoi, A, 2003)
" The need for daily dosing to achieve optimal radioprotection was consistent with the tissue pharmacokinetics of the active metabolite."	2.42	Effects of dose and schedule on the efficacy of ethyol: preclinical studies. ( Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G, 2003)
"Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers."	2.42	Radiotherapy-induced salivary dysfunction. ( Hu, K; Ship, JA, 2004)
" Multiple-dose studies in rats show radioprotective effects equal to or greater than those obtained with intravenous dosing in the setting of fractionated irradiation."	2.41	Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. ( Bachy, CM; Cassatt, DR; Fazenbaker, CA; Kifle, G, 2002)
" Subcutaneous dosing is currently being assessed with the aim of improving ease of administration and potentially further improving tolerability."	2.41	Improved tolerability of amifostine with rapid infusion and optimal patient preparation. ( Boccia, R, 2002)
"Radiation-induced esophagitis is a frequent acute side effect in curative and palliative radiotherapy of thoracal and cervical tumors."	2.40	Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. ( Feldmann, HJ; Geinitz, H; Zimmermann, FB, 1998)
" It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy."	2.39	[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy]. ( Chomiczewski, K; Jabłońska, H; Wrembel-Wargocka, J, 1996)
"Acute pericarditis was detected in all rats receiving radiotherapy."	1.72	Could Amifostine Prevent Experimental Radiotherapy-Induced Acute Pericarditis? ( Bahat, Z; Caner Karahan, S; Cobanoglu, U; Kalyoncu, Nİ; Ulku, C; Yavuz, MN, 2022)
"All three breast cancer cells lines exhibited radiosensitivity with substantial cell death."	1.56	Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro. ( Buchman, LK; Buchman, SR; Cohen, MS; Donneys, A; Luby, AO; Lynn, JV; Nelson, NS; Subramanian, C; Urlaub, KM, 2020)
" polysaccharide (SNP) in combination with WR-2721, rhIL-11 and rhG-CSF on irradiated mice."	1.42	Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice. ( Chen, W; He, Y; Jiang, D; Jiang, S; Liu, Y; Shen, X, 2015)
"Head and neck cancer is treated mainly with surgery and radiotherapy."	1.36	Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients. ( Henríquez-Hernández, LA; Lara, PC; Lloret, M; Pinar, B; Rodríguez-Gallego, C; Saavedra, MM, 2010)
"Patients with localized prostate cancer received amifostine as a rectal suspension 30-45 minutes before daily three-dimensional conformal radiation therapy."	1.35	Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. ( Albert, PS; Camphausen, K; Coleman, CN; Cooley-Zgela, T; Crouse, NS; Godette, D; Guion, P; Ménard, C; Sciuto, LC; Simone, NL; Singh, AK; Smith, S; Soule, BP, 2008)
"For all the chromosome aberrations considered, a negative correlation between their initial yield and the percentage of this yield remained 12 months after radiotherapy was observed (p < 0."	1.35	Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence. ( Barquinero, JF; Barrios, L; Caballín, MR; Craven-Bartle, J; de Vega, JM; Ribas, M; Xunclà, M, 2008)
"Kojic acid was administrated subcutaneously as single doses of 142, 175, 232, and 350 mg/kg, one hour prior to a lethal dose of gamma irradiation (8 Gy)."	1.35	Radioprotective effects of kojic acid against mortality induced by gamma irradiation in mice. ( Ahmadi, A; Emami, S; Hosseinimehr, SJ; Moslemi, D; Zakaryaee, V, 2009)
"Esophagitis is a major complication of chemoradiation therapy in patients with non-small cell lung cancer, producing significant morbidity and resulting in treatment interruptions."	1.33	Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. ( Langer, C; Movsas, B; Werner-Wasik, M, 2005)
"A cohort of 32 breast cancer patients, pretreated with conservative surgery and adjuvant doxorubicin or taxane based chemotherapy, were treated with hypoARC."	1.33	Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery. ( Ambatzoglou, J; Koukourakis, MI; Manavis, J; Sismanidou, K, 2006)
"Patients with well-differentiated thyroid cancer have a good prognosis but a significant chance for local recurrence."	1.32	Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. ( Elkins, D; Goffman, TE; Karakla, D; Mason, ME; Mendoza, A; Shaffer, B, 2004)
" The dose-volume histogram (DVH) data were used to estimate the local dose-response relationship for loss of DL(CO)."	1.32	The relationship between local dose and loss of function for irradiated lung. ( Forster, KM; Gopal, R; Kelly, JF; Komaki, R; Liao, Z; Starkschall, G; Stevens, C; Tucker, SL, 2003)
"A total of 117 cancer patients with carcinomas localized in pelvic organs, lung and head and neck were entered into this study."	1.31	Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis. ( Balafouta, M; Kokakis, J; Kouloulias, V; Kouvaris, J; Matsopoulos, G; Miliadou, A; Vlahos, L, 2002)
"The degree of xerostomia has been reported to depend on the radiation dose and the salivary gland volume irradiated."	1.31	Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. ( Chao, KS, 2002)
"Esophageal cancer is treated optimally with a combined-modality approach according to most clinical investigators."	1.31	Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. ( Jatoi, A; Thomas, CR, 2002)
"Chemoradiation induced oral mucositis was delayed and showed significant lower degrees at all 10 Gy increments (p < 0."	1.30	Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. ( Bank, P; Beleites, E; Koscielny, S; Trog, D; Wendt, TG, 1999)

Research

Studies (178)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Number of Patients With Acute Grade 3/4 Toxicity (Excluding Grade 3 Leukopenia)

Timeframe	Studies, this research(%)	All Research%
pre-1990	8 (4.49)	18.7374
1990's	24 (13.48)	18.2507
2000's	109 (61.24)	29.6817
2010's	32 (17.98)	24.3611
2020's	5 (2.81)	2.80

Authors	Studies
Arora, A	1
Bhuria, V	1
Singh, S	1
Pathak, U	1
Mathur, S	1
Hazari, PP	1
Roy, BG	1
Sandhir, R	1
Soni, R	1
Dwarakanath, BS	1
Bhatt, AN	1
Zhou, S	1
Li, Y	2
He, L	1
Chen, M	1
Li, W	1
Xiao, T	1
Guan, J	1
Qi, Z	1
Wang, Q	1
Li, S	1
Zhou, P	1
Wang, Z	1
Bahat, Z	1
Cobanoglu, U	1
Ulku, C	1
Kalyoncu, Nİ	1
Caner Karahan, S	1
Yavuz, MN	1
Khalifa, J	1
François, S	1
Rancoule, C	1
Riccobono, D	1
Magné, N	1
Drouet, M	1
Chargari, C	1
Luby, AO	1
Subramanian, C	1
Buchman, LK	1
Lynn, JV	2
Urlaub, KM	2
Nelson, NS	5
Donneys, A	5
Cohen, MS	1
Buchman, SR	5
Zhang, J	2
Li, K	1
Zhang, Q	1
Zhu, Z	1
Huang, G	1
Tian, H	1
Gurses, I	1
Ozeren, M	1
Serin, M	1
Yucel, N	1
Erkal, HS	1
Can, B	1
Atilgan, R	1
Pala, S	1
Kuloğlu, T	1
Kiray, S	1
Ilhan, N	1
Carey, EG	1
Polyatskaya, Y	2
Mazzoli, AC	1
Radvansky, LJ	1
Pace, MB	1
Siddiqui, A	1
Ozdemir, CS	1
Burgazli, KM	1
Beken-Ozdemir, E	1
Akdere, H	1
Mericliler, M	1
Ozcelik, MF	1
Kuntić, VS	1
Stanković, MB	1
Vujić, ZB	1
Brborić, JS	1
Uskoković-Marković, SM	1
Maier, P	1
Wenz, F	1
Herskind, C	1
Li, CJ	1
Wang, SZ	1
Wang, SY	1
Zhang, YP	1
Gu, J	1
Zhu, S	1
Li, X	1
Wu, H	1
Hua, F	1
Vasin, MV	1
Ushakov, IB	1
Felice, PA	1
Page, EE	1
Deshpande, SS	3
Rodriguez, J	1
Shen, X	2
Xing, S	1
Xiong, GL	1
Xie, L	1
Guo, LL	1
Qiu, ZL	1
Ge, CH	1
Dai, CL	1
Luo, QL	1
Liu, XY	1
Yu, ZY	1
Liu, W	1
Chen, Q	2
Wu, S	1
Xia, X	1
Wu, A	1
Cui, F	1
Gu, YP	1
Zhang, X	1
Cao, J	1
Jiang, S	1
Liu, Y	2
He, Y	1
Jiang, D	1
Chen, W	1
Blanchard, P	2
Bourhis, J	5
Lacas, B	1
Le Teuff, G	1
Michiels, S	1
Pignon, JP	2
Singh, VK	1
Romaine, PL	1
Seed, TM	1
Devine, A	1
Marignol, L	1
Perosky, JE	1
Rodriguez, JJ	1
Figueredo, C	1
Vasseli, CA	1
Ratliff, HC	1
Kozloff, KM	1
Xu, Y	1
Wu, D	1
Fan, Y	1
Li, P	1
Du, H	1
Shi, J	1
Wang, D	1
Zhou, X	1
Monson, LA	1
Farberg, AS	1
Tchanque-Fossuo, CN	1
Rudat, V	3
Münter, M	1
Rades, D	2
Grötz, KA	1
Bajrovic, A	2
Haberkorn, U	1
Brenner, W	2
Debus, J	1
Mell, LK	1
Movsas, B	5
Kaldir, M	1
Cosar-Alas, R	1
Cermik, TF	1
Yurut-Caloglu, V	1
Saynak, M	1
Altaner, S	1
Caloglu, M	1
Kocak, Z	1
Tokatli, F	1
Türe, M	1
Parlar, S	1
Uzal, C	1
Rodrigues, NA	1
Killion, L	1
Hickey, G	1
Silver, B	1
Martin, C	1
Stevenson, MA	1
Mauch, PM	1
Ng, AK	1
Koukourakis, MI	8
Tsoutsou, PG	1
Abatzoglou, I	1
Hosseinimehr, SJ	1
Emami, S	1
Zakaryaee, V	1
Ahmadi, A	1
Moslemi, D	1
Okumura, H	1
Nasu, M	1
Yosue, T	1
Ma, C	1
Xie, J	1
Wang, G	1
Zuo, S	1
Meyer, AK	1
Young, NM	1
Ma, DY	1
Qiu, WL	1
Zhang, CP	1
Citrin, D	1
Cotrim, AP	1
Hyodo, F	1
Baum, BJ	1
Krishna, MC	1
Mitchell, JB	1
Katsanos, KH	1
Briasoulis, E	1
Tsekeris, P	1
Batistatou, A	1
Bai, M	1
Tolis, C	1
Capizzello, A	1
Panelos, I	1
Karavasilis, V	1
Christodoulou, D	1
Tsianos, EV	1
Saavedra, MM	1
Henríquez-Hernández, LA	1
Lara, PC	1
Pinar, B	1
Rodríguez-Gallego, C	1
Lloret, M	1
Maillard, E	1
Brizel, DM	5
Buentzel, J	2
Langendijk, JA	1
Komaki, R	5
Swan Leong, S	1
Levendag, P	3
Kyrgias, G	2
Papadopoulou, A	2
Panteliadou, M	2
Giatromanolaki, A	2
Sivridis, E	1
Mavropoulou, S	1
Kalogeris, K	1
Nassos, P	1
Milioudis, N	1
Touloupidis, S	1
Small, W	4
Winter, K	1
Levenback, C	1
Iyer, R	1
Hymes, SR	1
Jhingran, A	1
Gaffney, D	1
Erickson, B	1
Greven, K	1
Cakmak, G	1
Miller, LM	1
Zorlu, F	1
Severcan, F	1
Feng, M	1
Smith, DE	1
Normolle, DP	1
Knol, JA	1
Pan, CC	1
Ben-Josef, E	3
Lu, Z	1
Feng, MR	1
Chen, J	1
Ensminger, W	1
Lawrence, TS	1
Tsiarkatsi, M	1
Papachristou, E	1
Bebeli, M	1
Kouvaris, J	1
Kouloulias, V	1
Kokakis, J	1
Matsopoulos, G	3
Balafouta, M	1
Miliadou, A	1
Vlahos, L	1
Huang, R	1
Yu, H	1
Kuang, A	1
Cassatt, DR	4
Fazenbaker, CA	4
Kifle, G	3
Bachy, CM	4
Boccia, R	1
Myerson, R	2
Zobeiri, I	1
Birnbaum, E	1
Dietz, D	1
Fleshman, J	1
Kodner, I	1
Picus, J	1
Ratkin, G	1
Senzer, N	3
Bardet, E	1
Martin, L	1
Calais, G	1
Tuchais, C	1
Rhein, B	1
Feham, N	1
Alphonsi, M	1
Rosine, D	1
Braaksma, M	2
Anné, PR	2
Gopal, R	1
Tucker, SL	1
Liao, Z	3
Forster, KM	1
Stevens, C	1
Kelly, JF	2
Starkschall, G	1
Leong, SS	1
Tan, EH	1
Fong, KW	1
Wilder-Smith, E	1
Ong, YK	1
Tai, BC	1
Chew, L	1
Lim, SH	1
Wee, J	1
Lee, KM	1
Foo, KF	1
Ang, P	1
Ang, PT	1
Mandel, SJ	1
Mandel, L	1
Overgaard, J	1
Antonadou, D	5
Throuvalas, N	4
Petridis, A	2
Bolanos, N	2
Sagriotis, A	2
Synodinou, M	4
Momm, F	2
Weissenberger, C	1
Bartelt, S	1
Henke, M	3
Veslemes, M	1
Dziuk, T	1
Linares, LA	1
Echols, D	1
Hu, K	2
Ship, JA	3
Harrison, LB	1
Ménard, C	4
Camphausen, K	4
Muanza, T	1
Sears-Crouse, N	1
Smith, S	4
Coleman, CN	4
Jatoi, A	2
Haddad, R	1
Wirth, L	1
Costello, R	1
Weeks, L	1
Posner, M	1
Samuels, MA	1
Chico, IM	1
Hirsch, RL	1
Fullmer, K	1
Thorstad, WL	2
Haughey, B	2
Chao, KS	5
Ozyigit, G	1
Thorsdad, WL	1
Fehlauer, F	1
Mahlmann, B	1
Richter, E	1
Alberti, W	1
Mendoza, A	1
Shaffer, B	1
Karakla, D	1
Mason, ME	1
Elkins, D	1
Goffman, TE	1
Belkacémi, Y	1
Pasquier, D	1
Castelain, B	1
Warnet, JM	1
Lartigau, E	1
Kouloulias, VE	2
Kouvaris, JR	2
Pissakas, G	2
Kokakis, JD	2
Antypas, C	2
Mallas, E	2
Michopoulos, S	2
Vosdoganis, SP	1
Kostakopoulos, A	1
Vlahos, LJ	2
Aframian, DJ	1
Palmon, A	1
Nahlieli, O	1
Guelman, LR	1
Cabana, JI	1
del Luján Pagotto, RM	1
Zieher, LM	1
Scott, C	1
Langer, C	2
Werner-Wasik, M	4
Nicolaou, N	1
Machtay, M	1
Smith, C	1
Axelrod, R	1
Sarna, L	1
Wasserman, T	2
Byhardt, R	1
Kutta, H	1
Kampen, U	1
Sagowski, C	1
Bohuslavizki, KH	1
Paulsen, F	1
Mystakidou, K	1
Rosenthal, DI	2
Blanco, AI	1
Chang, JY	1
Wu, X	1
Allen, PK	1
Milas, L	2
Fossella, FV	2
Travis, E	1
Spitz, MR	1
Wynn, RB	1
Mehta, V	1
Muanza, TM	1
Albert, PS	3
Godette, D	2
Crouse, NS	3
Cooley-Zgela, T	3
Sciuto, L	1
Andrieu, MN	1
Kurtman, C	1
Hicsonmez, A	1
Ozbilgin, K	1
Eser, E	1
Erdemli, E	1
van Agthoven, M	1
Nijdam, W	1
Uyl-de Groot, C	1
Sasse, AD	1
Clark, LG	1
Sasse, EC	1
Clark, OA	1
Micke, O	1
Adamietz, IA	1
Monnier, A	2
Glatzel, M	2
de Vries, A	1
Konings, AW	1
Faber, H	1
Vissink, A	1
Coppes, RP	1
Spadaro, JA	2
Horton, JA	1
Margulies, BS	1
Luther, J	1
Strauss, JA	1
Farnum, CE	1
Damron, TA	2
Ozsahin, M	1
Betz, M	1
Matzinger, O	1
Bron, L	1
Luthi, F	1
Pasche, P	1
Azria, D	1
Mirimanoff, RO	1
Zouhair, A	1
Garden, AS	1
Lewin, JS	1
Chambers, MS	1
de Castro, G	1
Federico, MH	1
Singh, AK	2
Guion, P	2
Simone, NL	2
Godette, DJ	1
Sciuto, LC	2
Coleman, J	1
Pinto, P	1
Fleischer, G	1
Dörr, W	1
Manavis, J	1
Ambatzoglou, J	1
Sismanidou, K	1
Rolleman, EJ	1
Forrer, F	1
Bernard, B	1
Bijster, M	1
Vermeij, M	1
Valkema, R	1
Krenning, EP	1
de Jong, M	1
Veerasarn, V	1
Phromratanapongse, P	1
Suntornpong, N	1
Lorvidhaya, V	1
Sukthomya, V	1
Chitapanarux, I	1
Tesavibul, C	1
Swangsilpa, T	1
Khorprasert, C	1
Shotelersuk, K	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Study to Evaluate Oral Chlorophyllin in Hemorrhagic Cystitis Secondary to Radiation Therapy for Pelvic Malignancies[NCT05348239]	Phase 2	24 participants (Anticipated)	Interventional	2022-03-26	Recruiting
A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes[NCT00012012]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2001-08-31	Completed
A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas[NCT00158691]	Phase 3	296 participants	Interventional	2001-03-31	Completed
Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients[NCT02922244]		150 participants (Actual)	Interventional	2016-05-31	Completed
Amifostine as a Rectal Protector During External Beam Radiotherapy for Prostate Cancer: A Phase II Study[NCT00040365]	Phase 2	30 participants (Actual)	Interventional	2002-06-30	Completed
A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer[NCT00022139]	Phase 2	56 participants (Actual)	Interventional	2002-01-31	Completed
A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitax[NCT00003313]	Phase 3	243 participants (Actual)	Interventional	1998-09-30	Completed
Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358]	Phase 1	0 participants (Actual)	Interventional		Withdrawn (stopped due to unable to obtain funding to conduct study)
"Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"[NCT03541772]	Phase 2	60 participants (Actual)	Interventional	2015-01-20	Completed
Normal Tissue Oxygenation Following Radiotherapy[NCT00677040]		20 participants (Actual)	Observational	2008-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The second part of this study (second arm) was designed to detect a 40% relative reduction (absolute from 77% to 46%) in the acute grade 3/4 toxicity (excluding grade 3 leukopenia) rate, with the addition of amifostine. A one-sided alpha of 0.05 and 80% power required 16 evaluable patients to detect the hypothesized difference. If ≤ 8 had the toxicity, it would be concluded that adding amifostine decreased this toxicity rate by at least 40%. (NCT00012012)
Timeframe: From start of treatment to 90 days

Rate of Acute Grade 3/4 Toxicity (Excluding Grade 3 Leukopenia)

Intervention	participants (Number)
Radiation Therapy Plus Cisplatin and Amifostine	13

To determine the feasibility and tolerance of extended-field external radiotherapy to the pelvis and para-aortic region and intracavitary irradiation combined with weekly cisplatin using the rate of acute grade 3/4 toxicity rate (excluding grade 3 leukopenia). The first part of this study was designed to determine the acute grade 3/4 toxicity rate (excluding grade 3 leukopenia), to have a starting point for the second part (second arm) of the study. (NCT00012012)
Timeframe: From start of treatment to 90 days

Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment Over Time (Late Follow-up 18 Months)

Intervention	percentage of participants (Number)
Radiation Therapy Plus Cisplatin	81

The EPIC bowel assessment is a 26 item short form evaluation that assess patient function and bother after prostate treatment. The Expanded Prostate Cancer Index Composite is a self assessment questionnaire designed to measure quality of life in patients with prostate cancer. The questionnaire is scored on a scale of 0-100 with higher scores correlated with higher function and quality of life. For this study, the Bowel Domain was analyzed alongside the RTOG acute and late gastrointestinal morbidity scores. For details re: EPIC, see http://www.med.umich.edu/urology/research/EPIC/EPIC-2.2002.pdf (NCT00040365)
Timeframe: 18 months

Number of Participants Who Had Proctoscopic Examinations

Intervention	scores on a scale (Mean)
Amifostine	0.6

Proctoscopic scoring of mucosal change was performed according to a descriptive scale, described by Wachter et al, which assigns grades of mucosal congestion, telangiectasia, ulcerations, stricture, and necrosis. (NCT00040365)
Timeframe: 3 years

Number of Participants With Adverse Events

Intervention	Participants (Number)
Amifostine	30

Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00040365)
Timeframe: 3 years

Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With High Dose, 3D Conformal Radiotherapy for Prostate Cancer.

Intervention	Participants (Number)
Amifostine	30

A good toxicity outcome is defined as having less than grade 2 on both weeks 5 and 7 of treatment. The Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity scoring scheme and the Rectal Mucosal Toxicity response criteria will be used to assess rectal toxicity. The RTOG measures the rectal toxicities. The physician assigns a grade based on symptoms reported by the patient. For details about the RTOG (method and scoring of radiation morbidity, etc.) see http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx (NCT00040365)
Timeframe: RTOG Acute was used on week 5 and 7

Percentage of Participants With a Good Toxicity Outcome Who Experienced Late Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With High Dose, 3D Conformal Radiotherapy for Prostate Cancer.

Intervention	Percentage of Participants (Number)
Amifostine	20.69

A good toxicity outcome is defined as having less than grade 2 on both weeks 5 and 7 of treatment. Week 5, 7 were during treatment measuring acute toxicity. The Radiation Therapy Oncology Group (RTOG) Acute radiation morbidity scoring scheme and the Rectal Mucosal Toxicity response criteria will be used to assess rectal toxicity. The RTOG measures the rectal toxicities. The physician assigns a grade based on symptoms reported by the patient. For details about the RTOG see http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx. (NCT00040365)
Timeframe: The late rectal toxicity has been assessed at 1, 3, 6, 12, 18, 24, 36, and 60 months after the completion of treatment.

Measures of Quality of Life (QOL)-(Late Follow-up 18 Months)

Intervention	Percentage of Participants (Number)
Amifostine	83.33

Radiation toxicity consists of the Radiation Therapy Oncology Group(RTOG)acute(within 90 days of treatment)and RTOG late(>90days after treatment). This scoring system assigns a toxicity grade (0-4) based on symptoms with 0 being the best outcome. The Expanded Prostate Cancer Index Composite(EPIC) questionnaire consists of 50 quality of life items divided into 4 domains, urinary, bowel, sexual and hormonal. Each independent domain renders a scoring of 0-100 with 100 being the best score. The EPIC and RTOG scores were correlated not combined. (NCT00040365)
Timeframe: Baseline, week 5, 7 , and months 1, 3, 6, 12, and 18

Tissue Oxygenation

Intervention	scores on a scale (Mean)
	Baseline bowel function	Baseline bowel bother	Week 5 bowel function	Week 5 bowel bother	Week 5 RTOG	Week 7 bowel function	Week 7 bowel bother	Week 7 RTOG	1 month bowel function	1 month bowel bother	1 month RTOG	3 month bowel function	3 month bowel bother	3 month RTOG	6 month bowel function	6 month bowel bother	6 month RTOG	12 month bowel function	12 month bowel bother	12 month RTOG	18 month bowel function	18 month bowel bother	18 month RTOG
Amifostine	91.13	92.86	71.43	67.33	1.06	69.76	66.38	1.00	84.09	78.08	0.59	79.08	82.78	0.54	85.46	81.86	0.39	83.92	77.65	0.50	83.55	76.28	0.64

Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes

Intervention	Participants (Count of Participants)
	late subcutaneous toxicitiy score 1	late subcutaneous toxcity score 2	late skin toxicity score 1	late skin toxicity score 2
Subjects	19	1	19	1

Article	Year
Gene therapy and cell therapy for the management of radiation damages to healthy tissues: Rationale and early results. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2019, Volume: 23, Issue:5 Topics: Amifostine; Animals; Antioxidants; Cell- and Tissue-Based Therapy; Clinical Trials as Topic; Dose Fr	2019
Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jun-15, Volume: 70, Issue:12 Topics: Administration, Topical; Amifostine; Analgesics; Antineoplastic Protocols; Combined Modality Therapy	2013
Radioprotectors - the evergreen topic. Chemistry & biodiversity, 2013, Volume: 10, Issue:10 Topics: Amifostine; Antioxidants; Biological Products; Humans; Plants; Polyphenols; Radiation Injuries; Radi	2013
Radioprotection of normal tissue cells. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014, Volume: 190, Issue:8 Topics: Amifostine; Cell Survival; Clinical Trials as Topic; DNA Damage; Dose Fractionation, Radiation; Fibr	2014
Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials. PloS one, 2014, Volume: 9, Issue:5 Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Ra	2014
Comparative efficacy and the window of radioprotection for adrenergic and serotoninergic agents and aminothiols in experiments with small and large animals. Journal of radiation research, 2015, Volume: 56, Issue:1 Topics: 5-Methoxytryptamine; Adrenergic Agents; Amifostine; Animals; Cricetinae; Dogs; Dose-Response Relatio	2015
[Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:3 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Ch	2015
Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile. Health physics, 2015, Volume: 108, Issue:6 Topics: Amifostine; Androstenediol; Animals; Drug Approval; Granulocyte Colony-Stimulating Factor; Humans; M	2015
Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. Anticancer research, 2016, Volume: 36, Issue:1 Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chi-Square Distribution; Humans; Lung	2016
Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine. Expert opinion on drug metabolism & toxicology, 2008, Volume: 4, Issue:10 Topics: Amifostine; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Neoplasms; Radiation	2008
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer. The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4 Topics: Adenocarcinoma, Follicular; Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiatio	2009
Auditory late effects of chemotherapy. Cancer treatment and research, 2009, Volume: 150 Topics: Adolescent; Adult; Age Factors; Amifostine; Animals; Antineoplastic Agents; Brain Neoplasms; Child;	2009
[Current status of prevention and management of radiation-induced xerostomia]. Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2010, Volume: 45, Issue:2 Topics: Amifostine; Animals; Head and Neck Neoplasms; Humans; Oral Health; Radiation Injuries; Radiation-Pro	2010
Radioprotectors and mitigators of radiation-induced normal tissue injury. The oncologist, 2010, Volume: 15, Issue:4 Topics: Amifostine; Animals; Antioxidants; Cyclic N-Oxides; DNA Damage; Fibroblast Growth Factor 7; Free Rad	2010
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-S	2011
[Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2002, Volume: 19, Issue:4 Topics: Amifostine; Animals; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials,	2002
Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Animals; Biological Availability; Cytoprotection; Drug Evaluation, Preclinical; Injectio	2002
Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Cytoprotection; Humans; Infusions, Intr	2002
Potential for use of amifostine in cervical cancer. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Ph	2002
Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Apoptosis; Breast Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Combined Modality T	2002
Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoprotection; Drug Evaluation, Pre	2002
Radioactive iodine and the salivary glands. Thyroid : official journal of the American Thyroid Association, 2003, Volume: 13, Issue:3 Topics: Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiation Injuries; Radiation-Protec	2003
Amifostine: is there evidence of tumor protection? Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dog	2003
Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Animals; Injections, Intravenous; Injections, Subcutaneous; Macaca fascicularis; Mercapt	2003
Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Brachytherapy; Clinical Trials as Topic; Feasibility Studies; Humans; Male; Prostatic Ne	2003
Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Intraoperative Period; Postop	2003
Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine? Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Esophageal N	2003
Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Adolescent; Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hum	2003
[Radiation protectants of the crystalline lens]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7 Suppl 1 Topics: Amifostine; Anethole Trithione; Animals; Apoptosis; Cataract; Cattle; Cell Cycle; Cells, Cultured; C	2003
Radiotherapy-induced salivary dysfunction. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Intraoperative Period; Radia	2004
Head and neck squamous cell carcinoma: optimizing the therapeutic index. Expert review of anticancer therapy, 2005, Volume: 5, Issue:3 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal	2005
Treatment-related esophagitis. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3 Topics: Amifostine; Antineoplastic Agents; Dose Fractionation, Radiation; Esophagitis; Humans; Lung Neoplasm	2005
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3 Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad	2006
How to reduce radiation-related toxicity in patients with cancer of the head and neck. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Amifostine; Anti-Infective Agents; Deglutition Disorders; Fibrosis; Free Radical Scavengers; Growth	2006
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. Current opinion in oncology, 2006, Volume: 18, Issue:3 Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical S	2006
Management of salivary hypofunction during and after radiotherapy. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103 Suppl Topics: Amifostine; Dental Caries; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Radiation-P	2007
Cytoprotection for radiation-associated normal tissue injury. Cancer treatment and research, 2008, Volume: 139 Topics: Amifostine; Clinical Trials as Topic; Cytoprotection; Humans; Neoplasms; Radiation Injuries; Radiati	2008
Clinical status of the new cytoprotective agent, amifostine. Oncology (Williston Park, N.Y.), 1994, Volume: 8, Issue:7 Topics: Agranulocytosis; Amifostine; Antineoplastic Agents; Bone Marrow Purging; Drug Synergism; Granulocyte	1994
Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A Suppl 1 Topics: Amifostine; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Humans; Ne	1995
Radiotherapeutic studies with amifostine (Ethyol). Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 11 Topics: Amifostine; Animals; Cell Survival; Clinical Trials as Topic; Colony-Forming Units Assay; Humans; Ne	1994
Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 11 Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Female; Humans; Male; Ne	1994
[Amifostine: current and future applications in cytoprotection]. Bulletin du cancer, 1996, Volume: 83, Issue:9 Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem	1996
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 4 Topics: Amifostine; Animals; Antineoplastic Agents; Mice; Neoplasms, Experimental; Radiation Injuries; Radia	1996
[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy]. Przeglad lekarski, 1996, Volume: 53, Issue:11 Topics: Amifostine; Antineoplastic Agents; Hematologic Diseases; Humans; Kidney Diseases; Neoplasms; Nervous	1996
Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environmental health perspectives, 1997, Volume: 105 Suppl 6 Topics: Amifostine; Animals; Government Agencies; Humans; Mice; Occupational Diseases; Radiation Injuries; R	1997
Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine. Seminars in radiation oncology, 1998, Volume: 8, Issue:4 Suppl 1 Topics: Amifostine; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase II as T	1998
Therapy and prophylaxis of acute and late radiation-induced sequelae of the esophagus. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174 Suppl 3 Topics: Amifostine; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Deglutition Diso	1998
Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174 Suppl 3 Topics: Acute Disease; Amifostine; Humans; Intestinal Mucosa; Proctitis; Radiation Injuries; Radiation-Prote	1998
Clinical status and optimal use of amifostine. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:1 Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow Cells; Clinical Trials, Phase III as Topic;	1999
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1999, Volume: 221, Issue:1 Topics: Adrenergic beta-Agonists; Amifostine; Animals; Head and Neck Neoplasms; Humans; Iatrogenic Disease;	1999
Has the outlook improved for amifostine as a clinical radioprotector? Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2000, Volume: 57, Issue:2 Topics: Amifostine; Animals; Clinical Trials as Topic; Disease Models, Animal; Dogs; Dose-Response Relations	2000
The role of amifostine as a radioprotector. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:10 Topics: Amifostine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials,	2001
The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fe	2002
Pharmacokinetics of WR-2721. Pharmacology & therapeutics, 1988, Volume: 39, Issue:1-3 Topics: Amifostine; Animals; Humans; Hydrolysis; Neoplasms; Neoplasms, Experimental; Organothiophosphorus Co	1988
Specific protection of different normal tissues. Pharmacology & therapeutics, 1988, Volume: 39, Issue:1-3 Topics: Amifostine; Animals; Humans; Radiation Injuries; Radiation Injuries, Experimental; Radiation-Protect	1988

Article	Year
A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. International journal of radiation oncology, biology, physics, 2009, Nov-15, Volume: 75, Issue:4 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,	2009
Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. Journal of experimental & clinical cancer research : CR, 2010, Jun-10, Volume: 29 Topics: Adult; Aged; Amifostine; Colitis; Combined Modality Therapy; Endometrial Neoplasms; Female; Follow-U	2010
Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy. Anticancer research, 2011, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Amifostine; Cytoprotection; Dose Fractionation, Radiation; Feasibility Stud	2011
Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:7 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Brachytherapy; Carcinoma; Cisplatin; Female; Humans;	2011
A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. International journal of radiation oncology, biology, physics, 2012, Aug-01, Volume: 83, Issue:5 Topics: Adult; Aged; Amifostine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; C	2012
Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy. American journal of clinical oncology, 2013, Volume: 36, Issue:4 Topics: Adult; Aged; Amifostine; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Dose-Respo	2013
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti	2002
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non	2002
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Carcinoma, Squamous Cell; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Injec	2002
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotecti	2002
Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Adult; Aged; Amifostine; Cytoprotection; Dose Fractionation, Radiation; Female; Head and Neck Neopla	2002
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non	2003
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 2003, Oct-01, Volume: 57, Issue:2 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L	2003
Moist skin care can diminish acute radiation-induced skin toxicity. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2003, Volume: 179, Issue:10 Topics: Amifostine; Azulenes; Clinical Trials as Topic; Data Interpretation, Statistical; Dose Fractionation	2003
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modal	2003
Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Aged; Amifostine; Brachytherapy; Humans; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries;	2003
Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Agents; Brachytherapy; Cisplatin; Combined Modality Therapy; Female; Huma	2003
Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Adenocarcinoma; Administration, Rectal; Aged; Amifostine; Humans; Male; Middle Aged; Prostatic Neopl	2003
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C	2003
Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Aged; Amifostine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Radiation	2003
Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Pil	2003
Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Adolescent; Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hum	2003
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2004, Volume: 70, Issue:3 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C	2004
A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2004, Volume: 180, Issue:9 Topics: Administration, Rectal; Administration, Topical; Aged; Amifostine; Feasibility Studies; Humans; Inte	2004
Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Hum	2004
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10 Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-	2005
Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. International journal of radiation oncology, biology, physics, 2005, Jun-01, Volume: 62, Issue:2 Topics: Administration, Rectal; Amifostine; Female; Genital Neoplasms, Female; Humans; Injections, Subcutane	2005
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-S	2005
Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. International journal of radiation oncology, biology, physics, 2005, Aug-01, Volume: 62, Issue:5 Topics: Aged; Amifostine; Chi-Square Distribution; Humans; Male; Middle Aged; Proctoscopy; Prostatic Neoplas	2005
Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:14 Topics: Ambulatory Care; Amifostine; Brachytherapy; Combined Modality Therapy; Costs and Cost Analysis; Fema	2005
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Disease Prog	2006
Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:12 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Chi-Square Distribution; Female; Head and Neck Ne	2006
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ	2007
Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid : official journal of the American Thyroid Association, 2008, Volume: 18, Issue:3 Topics: Adult; Aged; Amifostine; Cell Differentiation; Combined Modality Therapy; Cytoprotection; Female; Hu	2008
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Amifostine; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combine	1993
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:8 Topics: Adult; Aged; Amifostine; Calcitriol; Calcium; Calcium, Dietary; Cisplatin; Combined Modality Therapy	1993
[Amifostine: current and future applications in cytoprotection]. Bulletin du cancer, 1996, Volume: 83, Issue:9 Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow; Disease Models, Animal; Drug Tolerance; Hem	1996
Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L	1997
A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. International journal of radiation oncology, biology, physics, 2000, Mar-15, Volume: 46, Issue:5 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Eruptions; Fea	2000
Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:11 Topics: Abdominal Neoplasms; Adult; Aged; Amifostine; Chi-Square Distribution; Dose Fractionation, Radiation	2000
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi	2000
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi	2000
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi	2000
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi	2000
Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2000, Volume: 176, Issue:9 Topics: Amifostine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Fluoro	2000
Protective effect of amifostine on dental health after radiotherapy of the head and neck. International journal of radiation oncology, biology, physics, 2000, Dec-01, Volume: 48, Issue:5 Topics: Adult; Aged; Amifostine; Dental Caries; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged;	2000
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4 Topics: Acute Disease; Amifostine; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Premedica	2001
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International journal of radiation oncology, biology, physics, 2002, Mar-01, Volume: 52, Issue:3 Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Th	2002
Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combi	2002
A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Acute Disease; Amifostine; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Nausea; Radiat	2002
Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Acute Disease; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcin	2002
Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined	2002
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined	2002
Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Acute Disease; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality	2002
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Antineoplastic Agents; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response R	2002
Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Adenocarcinoma; Administration, Rectal; Amifostine; Humans; Male; Prostatic Neoplasms; Radiation Dos	2002
Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer, 1992, Jun-01, Volume: 69, Issue:11 Topics: Adult; Aged; Amifostine; Female; Humans; Male; Middle Aged; Preoperative Care; Radiation Injuries; R	1992
Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial. Cancer, 1992, Jun-01, Volume: 69, Issue:11 Topics: Administration, Topical; Amifostine; Drug Evaluation; Humans; Intestinal Mucosa; Proctocolitis; Radi	1992

Article	Year
Amifostine analog, DRDE-30, alleviates radiation induced lung damage by attenuating inflammation and fibrosis. Life sciences, 2022, Jun-01, Volume: 298 Topics: Amifostine; Animals; Inflammation; Lung; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Radiation Inj	2022
Haptoglobin is an early indicator of survival after radiation-induced severe injury and bone marrow transplantation in mice. Stem cell research & therapy, 2022, 09-06, Volume: 13, Issue:1 Topics: Amifostine; Animals; Bone Marrow Transplantation; Female; Haptoglobins; Humans; Mice; Mice, Inbred C	2022
Could Amifostine Prevent Experimental Radiotherapy-Induced Acute Pericarditis? Asian Pacific journal of cancer prevention : APJCP, 2022, Sep-01, Volume: 23, Issue:9 Topics: Amifostine; Animals; Antioxidants; Inflammation; Pericarditis; Radiation Injuries; Radiation-Protect	2022
Amifostine Prophylaxis in Irradiated Breast Reconstruction: A Study of Oncologic Safety In Vitro. Annals of plastic surgery, 2020, Volume: 85, Issue:4 Topics: Amifostine; Animals; Breast Neoplasms; Female; Humans; Mammaplasty; Radiation Injuries; Radiation-Pr	2020
Polycysteine as a new type of radio-protector ameliorated tissue injury through inhibiting ferroptosis in mice. Cell death & disease, 2021, 02-18, Volume: 12, Issue:2 Topics: Amifostine; Animals; Cell Line; Disease Models, Animal; DNA; Ferroptosis; Glutathione; Hematopoietic	2021
Histopathological efficiency of amifostine in radiation‑induced heart disease in rats. Bratislavske lekarske listy, 2018, Volume: 119, Issue:1 Topics: Amifostine; Animals; Cardiomyopathies; Heart; Male; Necrosis; Radiation Injuries; Radiation-Protecti	2018
Examination of the effect of ovarian radiation injury induced by hysterosalpingography on ovarian proliferating cell nuclear antigen and the radioprotective effect of amifostine: an experimental study. Drug design, development and therapy, 2018, Volume: 12 Topics: Amifostine; Animals; Female; Hysterosalpingography; Ovary; Proliferating Cell Nuclear Antigen; Radia	2018
Histologic Improvements in Irradiated Bone Through Pharmaceutical Intervention in Mandibular Distraction Osteogenesis. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2018, Volume: 76, Issue:12 Topics: Amifostine; Animals; Deferoxamine; Drug Therapy, Combination; Male; Mandible; Osteogenesis, Distract	2018
The effect of Amifostine (Ethyol) on intestinal anastomosis in rats with radiation enteritis. European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:10 Topics: Amifostine; Anastomosis, Surgical; Animals; Colon; Enteritis; Female; Hydroxyproline; Radiation Inju	2013
Assessment of the effect of local application of amifostine on acute radiation-induced oral mucositis in guinea pigs. Journal of radiation research, 2014, Volume: 55, Issue:5 Topics: Acute Disease; Administration, Topical; Amifostine; Animals; Guinea Pigs; Intercellular Adhesion Mol	2014
Amifostine reduces radiation-induced complications in a murine model of expander-based breast reconstruction. Plastic and reconstructive surgery, 2014, Volume: 134, Issue:4 Topics: Amifostine; Animals; Male; Mammaplasty; Models, Animal; Radiation Injuries; Radiation-Protective Age	2014
[Protective effect of HS-6101 on rhesus monkeys with severe hematopoietic acute radiation sickness]. Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:6 Topics: Amifostine; Animals; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Marrow Cells; Hematopoieti	2014
Radioprotector WR-2721 and mitigating peptidoglycan synergistically promote mouse survival through the amelioration of intestinal and bone marrow damage. Journal of radiation research, 2015, Volume: 56, Issue:2 Topics: Amifostine; Animals; Bone Marrow Diseases; Drug Synergism; Intestinal Diseases; Male; Mice; Mice, In	2015
Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice. Journal of radiation research, 2015, Volume: 56, Issue:3 Topics: Amifostine; Animals; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Interleukin-1	2015
Prevention of radiation-induced bone pathology through combined pharmacologic cytoprotection and angiogenic stimulation. Bone, 2016, Volume: 84 Topics: Amifostine; Angiography; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases; Cytoprotecti	2016
Novel Recombinant Protein FlaA N/C Protects against Radiation Injury via NF-κB Signaling. Radiation research, 2016, Volume: 185, Issue:1 Topics: Amifostine; Animals; Cytokines; Dose-Response Relationship, Radiation; Female; Flagellin; Mice; Mice	2016
Amifostine Treatment Mitigates the Damaging Effects of Radiation on Distraction Osteogenesis in the Murine Mandible. Annals of plastic surgery, 2016, Volume: 77, Issue:2 Topics: Amifostine; Animals; Bone Regeneration; Male; Mandible; Osteogenesis, Distraction; Radiation Injurie	2016
The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 89, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Female; Head and Neck Neoplasms; Humans; Mal	2008
Amifostine use in radiation-induced kidney damage. Preclinical evaluation with scintigraphic and histopathologic parameters. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008, Volume: 184, Issue:7 Topics: Amifostine; Animals; Female; Injections, Intraperitoneal; Kidney; Kidney Function Tests; Kidney Tubu	2008
Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine. American journal of clinical oncology, 2009, Volume: 32, Issue:3 Topics: Aged; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy;	2009
Radioprotective effects of kojic acid against mortality induced by gamma irradiation in mice. Saudi medical journal, 2009, Volume: 30, Issue:4 Topics: Amifostine; Animals; Antioxidants; Gamma Rays; Mice; Pyrones; Radiation Injuries; Radiation-Protecti	2009
Effects of amifostine administration prior to irradiation to the submandibular gland in mice: autoradiographic study using 3H-leucine. Okajimas folia anatomica Japonica, 2009, Volume: 85, Issue:4 Topics: Amifostine; Animals; Autoradiography; Leucine; Male; Mice; Mice, Inbred BALB C; Radiation Injuries;	2009
Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients. Journal of radiation research, 2010, Volume: 51, Issue:5 Topics: Adult; Aged; Amifostine; Apoptosis; Carcinoma, Squamous Cell; Cells, Cultured; Head and Neck Neoplas	2010
Radiation damage and radioprotectants: new concepts in the era of molecular medicine. The British journal of radiology, 2012, Volume: 85, Issue:1012 Topics: Amifostine; Bystander Effect; Humans; Neoplasms; Radiation Injuries; Radiation-Protective Agents	2012
Amifostine, a radioprotectant agent, protects rat brain tissue lipids against ionizing radiation induced damage: an FTIR microspectroscopic imaging study. Archives of biochemistry and biophysics, 2012, Apr-15, Volume: 520, Issue:2 Topics: Amifostine; Animals; Brain Injuries; Lipid Metabolism; Lipid Peroxidation; Male; Radiation Injuries;	2012
Cytoprotective effect of amifostine in radiation-induced acute mucositis - a retrospective analysis. Onkologie, 2002, Volume: 25, Issue:4 Topics: Acute Disease; Adult; Aged; Amifostine; Esophagus; Female; Gastric Mucosa; Humans; Male; Middle Aged	2002
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19 Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung	2002
The relationship between local dose and loss of function for irradiated lung. International journal of radiation oncology, biology, physics, 2003, May-01, Volume: 56, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplati	2003
Does amifostine have a role in chemoradiation treatment? The Lancet. Oncology, 2003, Volume: 4, Issue:6 Topics: Amifostine; Combined Modality Therapy; Humans; Neoplasms; Radiation Injuries; Radiation-Protective A	2003
Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model. International journal of radiation oncology, biology, physics, 2003, Nov-01, Volume: 57, Issue:3 Topics: Amifostine; Animals; Female; Injections, Intravenous; Injections, Subcutaneous; Mercaptoethylamines;	2003
Proceedings of the 3rd International Cytoprotection Investigators' Congress. May 15-18, 2003, Nevis, West Indies. Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18 Topics: Amifostine; Animals; Humans; Neoplasms; Radiation Injuries; Radiation-Protective Agents	2003
Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid : official journal of the American Thyroid Association, 2004, Volume: 14, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Chronic Disease; Fatigue; Fem	2004
[Future therapy strategies for salivary gland impairment]. Refu'at ha-peh veha-shinayim (1993), 2004, Volume: 21, Issue:3 Topics: Amifostine; Cranial Irradiation; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine;	2004
Ionizing radiation-induced damage on developing cerebellar granule cells cultures can be prevented by an early amifostine post-treatment. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2005, Volume: 23, Issue:1 Topics: Amifostine; Analysis of Variance; Animals; Animals, Newborn; Cell Count; Cell Survival; Cells, Cultu	2005
Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA. Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modal	2004
Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2005, Volume: 181, Issue:4 Topics: Amifostine; Animals; Female; Iodine Radioisotopes; Models, Animal; Rabbits; Radiation Injuries; Radi	2005
Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3 Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topi	2005
Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3 Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topi	2005
In vivo study to evaluate the protective effects of amifostine on radiation-induced damage of testis tissue. Oncology, 2005, Volume: 69, Issue:1 Topics: Amifostine; Animals; In Situ Nick-End Labeling; Male; Microscopy; Microscopy, Electron; Radiation In	2005
Radioprotective effect of amifostine on parotid gland functioning is region dependent. International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5 Topics: Amifostine; Animals; Male; Parotid Gland; Radiation Injuries; Radiation-Protective Agents; Rats; Rat	2005
Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone. International journal of radiation biology, 2005, Volume: 81, Issue:10 Topics: Amifostine; Animals; Anti-Ulcer Agents; Bone Development; Disease Models, Animal; Dose Fractionation	2005
Established and emerging uses of cytoprotection in head and neck cancer. Archives of otolaryngology--head & neck surgery, 2006, Volume: 132, Issue:2 Topics: Amifostine; Cytoprotection; Head and Neck Neoplasms; Humans; Radiation Injuries; Radiation-Protectiv	2006
Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy. Archives of otolaryngology--head & neck surgery, 2006, Volume: 132, Issue:2 Topics: Adult; Aged; Amifostine; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Feasi	2006
New approaches to preventing xerostomia. The journal of supportive oncology, 2006, Volume: 4, Issue:2 Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radi	2006
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. International journal of radiation oncology, biology, physics, 2006, Jul-15, Volume: 65, Issue:4 Topics: Administration, Rectal; Aged; Amifostine; Humans; Male; Pilot Projects; Proctitis; Prostatic Neoplas	2006
Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2006, Volume: 182, Issue:10 Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Inject	2006
Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery. American journal of clinical oncology, 2006, Volume: 29, Issue:5 Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Breast; Breast Neoplasms; Cohort Studies; Combined M	2006
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. European journal of nuclear medicine and molecular imaging, 2007, Volume: 34, Issue:5 Topics: Amifostine; Animals; Body Weight; Creatinine; Kidney; Lysine; Male; Neoplasms; Octreotide; Organomet	2007
Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. International journal of radiation oncology, biology, physics, 2008, Jan-01, Volume: 70, Issue:1 Topics: Adenocarcinoma; Administration, Rectal; Aged; Amifostine; Dose-Response Relationship, Drug; Follow-U	2008
Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents. International journal of radiation oncology, biology, physics, 2007, Oct-01, Volume: 69, Issue:2 Topics: Acute Disease; Amifostine; Animals; Antigens, Neoplasm; Body Weight; Chronic Disease; Drug Evaluatio	2007
Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence. International journal of radiation biology, 2008, Volume: 84, Issue:3 Topics: Amifostine; Chromosome Aberrations; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization,	2008
Survival of bone marrow-engrafted mice subsequent to protection from lethal radiation by WR 2721. Radiation research, 1980, Volume: 82, Issue:1 Topics: Amifostine; Animals; Bone Marrow Transplantation; Cobalt Radioisotopes; Gamma Rays; Lethal Dose 50;	1980
[Investigations on combined injuries, 29th communication. Protective effect of aminopropylamino-ethylthiophosphate (WR 2721) in mice with radiation and combined injuries (irradiation and skin wound or burn) (author's transl)]. Strahlentherapie, 1980, Volume: 156, Issue:8 Topics: Amifostine; Animals; Burns; Female; Mathematics; Mice; Organothiophosphorus Compounds; Radiation Dos	1980
Skin radioprotection by 5-thio-D-glucose. Radiation research, 1983, Volume: 93, Issue:2 Topics: Amifostine; Animals; Dose-Response Relationship, Radiation; Female; Foot Deformities, Acquired; Gluc	1983
Radiobiology and clinical radiotherapy. Texas medicine, 1984, Volume: 80, Issue:4 Topics: Amifostine; Animals; Fast Neutrons; Humans; Mice; Neoplasms; Radiation Dosage; Radiation Injuries; R	1984
Radioprotection of the rat small intestine with topical WR-2721. Cancer, 1994, Oct-15, Volume: 74, Issue:8 Topics: Administration, Topical; Amifostine; Animals; Female; Hydrogen-Ion Concentration; Intestinal Mucosa;	1994
Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer. International journal of radiation oncology, biology, physics, 1993, Jun-15, Volume: 26, Issue:3 Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Incidence; Infusion	1993
Effects of immunomodulators on postirradiation recovery in the thymus. Physiological research, 1997, Volume: 46, Issue:3 Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Amifostine; Animals; Atrophy; Bacteria; C	1997
Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175, Issue:9 Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Cohort Studies; Combined Modality Therapy; Dose F	1999
Sparing of radiation-induced damage to the physis: fractionation alone compared to amifostine pretreatment. International journal of radiation oncology, biology, physics, 2000, Jul-01, Volume: 47, Issue:4 Topics: Amifostine; Animals; Bone Development; Dose Fractionation, Radiation; Femur; Leg Length Inequality;	2000
[Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2001, Volume: 5, Issue:2 Topics: Amifostine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glutamine; Gran	2001
Highlights of the Eighth European Cancer Conference. Journal of the International Association of Physicians in AIDS Care, 1995, Volume: 1, Issue:11 Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Mo	1995
Role of endogenous thiols in protection. Advances in space research : the official journal of the Committee on Space Research (COSPAR), 1992, Volume: 12, Issue:2-3 Topics: Amifostine; Animals; Cells; Cysteamine; DNA Damage; DNA Repair; Free Radical Scavengers; Glutathione	1992
A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Animals; Clinical Trials, Phase II as Topic; Head and Neck Neoplasms; Humans; Hypothyroi	2002
Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Parotid Gland; R	2002
Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Eso	2002
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin	2002
Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1 Topics: Amifostine; Animals; Female; Head; Injections, Intravenous; Injections, Subcutaneous; Mouth Mucosa;	2002
Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmacology & therapeutics, 1988, Volume: 39, Issue:1-3 Topics: Alkylating Agents; Amifostine; Cisplatin; Cyclophosphamide; Drug Evaluation; Humans; Neoplasms; Orga	1988
Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury. International journal of radiation oncology, biology, physics, 1986, Volume: 12, Issue:6 Topics: Amifostine; Gallium Radioisotopes; Head and Neck Neoplasms; Humans; Organothiophosphorus Compounds;	1986

amifostine anhydrous and Injuries, Radiation